Perspectives on low-density-lipoprotein cholesterol goal achievement
The DOI matches its Crossref record; 96 of the 97 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elevated levels of low-density lipoprotein cholesterol (LDL-C) are associated with an increased risk of coronary heart disease (CHD). European and US guidelines now recommend lower LDL-C levels, particularly in high-risk patients. Although LDL-C treatment goals to reduce the risk of CHD are clear, many patients do not reach their LDL-C goals. OBJECTIVES: Examine consensus guideline targets for LDL-C lowering in patients at high or very high cardiovascular risk; examine cholesterol goal achievement in clinical practice; evaluate the effectiveness of ezetimibe/statin and other adjunctive lipid-lowering treatments in achieving LDL-C goals; and consider ongoing controversies and the randomized controlled trials that may help to resolve or better illuminate them. METHODS: An English-language PubMed search was conducted to identify prospective randomized controlled trials, open-label studies, and retrospective and observational studies from 2001 (same year that the executive summary of the National Cholesterol Education Program's Adult Treatment Panel III was published) to present for an analysis of the effects of adjunctive therapies on LDL-C lowering and goal attainment in patients at elevated cardiovascular risk. RESULTS: Elevated LDL-C is the primary target of lipid-lowering therapy; aggressive lowering is of great benefit to those at high risk. Statins are recommended first-line lipid-lowering agents, with a long, well-regarded history of efficacy and safety. Not all patients, however, can achieve recommended LDL-C goals simply using starting doses of statins. For such patients, more intensive therapy utilizing high-dose statins or combination therapy, including statins combined with other lipid-lowering agents, such as ezetimibe, bile acid resins (BARs), or niacin, is warranted. Potential limitations of the present review include possible publication bias and the focus on pharmacotherapy rather than lifestyle modification and the important objective of multiple risk-factor modification to reduce absolute global cardiovascular risk. CONCLUSIONS: With a well-established link between elevated LDL-C and cardiovascular risk, aggressive LDL-C lowering becomes particularly important. Patients needing intensive LDL-C lowering to achieve goals will often require adjunctive treatments, including ezetimibe, BARs, or niacin along with statins. Given both their high mg: mg potency in lowering LDL-C and favorable tolerability and patient acceptance/adherence profile, ezetimibe/statin combination regimens arguably provide the greatest likelihood for patients to reach new, lower LDL-C targets; however, efficacy and safety data of any adjunctive treatment, along with drug costs and patient adherence to treatment (partly related to complexity of the regimen) all need to be considered when determining the optimal regimen to achieve LDL-C goals in individual patients according to their baseline absolute cardiovascular risk, LDL-C level, and consensus LDL-C targets.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Current available evidence suggests that the clinical benefit is largely independent of the type of statin but depends on the extent of LDL-C lowering”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [100]
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236 · cited 10×
“438 Lowering LDL-C to goal 2009 Informa UK Ltd - Curr Med Res Opin 2009; 25(2)”
BackgroundInfluentialIntensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Research works printed but not linked: 8
- Scandinavian Simvastatin Survival Study Group, 1994, Lancet, 344, 1383
- Downs J, 1998, Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 279, 1615
- 10.1001/jama.257.16.2176 · doi:10.1001/jama.257.16.2176 · Paper page
- Stamler J, 1986, Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA, 256, 2823
- Gaddi A, 2007, Vasc Health Risk Manag, 3, 877
- 2005, Heart, 9, 1
- Laforest L, 2007, Presented at European Society of Cardiology
- Lipid Research Clinics, 1984, The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA, 251, 365
Cited by
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Self-citation2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citationESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Self-citationEzetimibe therapy: mechanism of action and clinical update
Toth, P., Phan, & Dayspring, T. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33664 · Cited by 288
“13 Institutional surveys have shown that only two-thirds of vascular disease patients are at an LDL-C goal of , 100 mg/dL and less than a third of very high-risk patients are able to reach an LDL-C goal of , 70 mg/dL. 14,15 Based upon these treatment failures, combination therapies using multiple…”
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.012 · Cited by 192
“Current available evidence suggests that the clinical benefit is largely independent of the type of statin but depends on the extent of LDL-C lowering; therefore, the type of statin used should reflect the degree of LDL-C reduction that is required to reach the target LDL-C in a given patient.(15,100) More details on…”
BackgroundSelf-citationCardiovascular risk and dyslipidemia among persons living with HIV: a review
Maggi, P., Biagio, A. D., Rusconi, S., Cicalini, S., D’Abbraccio, M., d’Ettorre, G., Martinelli, C. V., Nunnari, G., Sighinolfi, L., Spagnuolo, V., et al. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2626-z · Cited by 168
“Current available evidence suggests that the clinical benefit is largely independent of the type of statin but depends on the extent of LDL-C lowering; therefore, the type of statin used should reflect the degree of LDL-C reduction that is required to reach the target LDL-C in a given patient [56].”
BackgroundGuía de la ESC/EAS sobre el manejo de las dislipemias
Reiner, Ž., Catapano, A. L., Backer, G. D., Graham, I. M., Taskinen, M., Wiklund, O., Agewall, S., Alegría, E., Chapman, M. J., Durrington, P. N., et al. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.09.014 · Cited by 80
Self-citationAdherence to lipid-lowering treatment: the patient perspective
Catapano, A. L., Casula, M., & Tragni, E. (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29092 · Cited by 67
Self-citationSafety and tolerability of injectable lipid-lowering drugs: a review of available clinical data
Cicero, A. F., Tartagni, E., & Ertek, S. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.932348 · Cited by 39
“This strategy is overall effective and relatively well-tolerated; however, subjects at high risk for cardiovascular disease, those requiring more intensive treatment for cholesterolemia reduction, often do not reach the desired LDL cholesterol (LDLC) target, either because of the lack of efficiency of the available th…”
BackgroundLu, C. Y., Law, M. R., Soumerai, S. B., Graves, A. J., LeCates, R. F., Zhang, F., Ross‐Degnan, D., & Adams, A. S. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.01.012 · Cited by 38
Update on the efficacy and safety of combination ezetimibe plus statin therapy
Toth, P. P., Catapano, A. L., Tomassini, J. E., & Tershakovec, A. M. (2010) · Clinical Lipidology · doi:10.2217/clp.10.49 · Cited by 35
Self-citationHsu, H., Lin, C.-J., Lee, Y.-S., Wu, T., & Chien, K. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01567-1 · Cited by 38
Foody, J. M., Brown, W. V., Zieve, F. J., Adewale, A. J., Flaim, D., Lowe, R. S., Jones-Burton, C., & Tershakovec, A. M. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.06.051 · Cited by 31
“(3) a measurement greater than or equal to the specified upper limit of normal followed by a measurement lower than specified upper limit of normal that was taken 2 days after the last dose of study”
BackgroundTreatment of Rheumatoid Arthritis with Marine and Botanical Oils: Influence on Serum Lipids
Olendzki, B. C., Leung, K., Buskirk, S. V., Reed, G., & Zurier, R. B. (2011) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2011/827286 · Cited by 29
“Most pharmacological treatments of dyslipidemia address reduction of LDL cholesterol [36, 37].”
Cicero, A. F., Tartagni, E., & Ertek, S. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.902929 · Cited by 26
“This strategy is usually effective and relatively well-tolerated; however, subjects at high risk for cardiovascular disease, those requiring more intensive treatment for cholesterolemia reduction, often do not reach the desired LDL-C target, either because of lack of efficiency of the available therapies or because of…”
BackgroundQuek, R. G. W., Fox, K. M., Wang, L., Li, L., Gandra, S. R., & Wong, N. D. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.11.035 · Cited by 24
“These modifications may include dose escalation, switches to different LLT agents, or augmentation with other LLTs.1 Some statin treatment modifications may potentially be indicative of index statin intolerance and/or ineffectiveness.”
BackgroundProfile of evolocumab and its potential in the treatment of hyperlipidemia
Cicero, A. F. G., Colletti, A., & Borghi, C. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s67498 · Cited by 22
“This strategy is usually effective and relatively well tolerated; however, subjects at high risk for cardiovascular disease, ie, those requiring more intensive treatment for reduction of hypercholesterolemia, often do not reach the desired LDL cholesterol target, either because of lack of efficacy of the available the…”
Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients
Foody, J. M., Sajjan, S. G., Hu, X., Ramey, D. R., Neff, D., Tershakovec, A. M., Tomassini, J. E., Wentworth, C., & Tunceli, K. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.01.007 · Cited by 22
Reckless, J. P. D., Davies, G., Tunceli, K., Hu, X., & Brudi, P. (2010) · Value in Health · doi:10.1111/j.1524-4733.2010.00742.x · Cited by 24
The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia
Krysiak, R. G., Żmuda, W., & Okopień, B. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.00932.x · Cited by 19
Ruan, Z., jiang, B., Chen, J., Zhang, X., Lou, H., Xiang, M., Shao, Q.-X., & Wang, J. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.310 · Cited by 17
“Elevated low-density lipoprotein cholesterol (LDL-C) levels are positively associated with the incidence of cardiovascular events.1 Evidence is mounting from clinical trials that reducing the levels of total cholesterol and LDL-C, and increasing high-density lipoprotein cholesterol (HDL-C) levels by dietary and/or pha…”
BackgroundEzetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes
Rotella, C. M., Zaninelli, A., Grazie, C. L., Hanson, M. E., & Gensini, G. F. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-80 · Cited by 18
Amuzie, C. J., Swart, J., Rogers, C. S., Vihtelic, T. S., Denham, S., & Mais, D. E. (2016) · Toxicologic Pathology · doi:10.1177/0192623315622304 · Cited by 16
“In humans, loss-of-function mutations in the low-density lipoprotein receptor (LDLR) gene led to familial hypercholesterolemia, which is associated with elevated plasma concentrations of total and LDL cholesterol (Catapano 2009).”
BackgroundLing, P. K. H., Civeira, F., Dan, A. G., Hanson, M. E., Massaad, R., Tilleghem, C. L. B. D., Milardo, C., & Triscari, J. M. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-18 · Cited by 14
“Despite substantial lipid-lowering with the use of statins, a considerable number of patients at high cardiovascular risk and/or with severely elevated low-density lipoprotein cholesterol (LDL-C) do not achieve the rigorous treatment targets recommended by European, Canadian and US guidelines [1-4].”
BackgroundEzetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients
Averna, M. R., Zaninelli, A., Grazie, C. L., & Gensini, G. F. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.05.002 · Cited by 14
“’’ It has been suggested that reducing cholesterol absorption with the use of ezetimibe treatment combined with statins to lower hepatic cholesterol synthesis may be a practical approach to intensive lipid management and goal achievement compared with treatments that reduce synthesis alone (ie, statins) in patients wi…”
BackgroundViigimaa, M., Vaverková, H., Farnier, M., Averna, M. R., Missault, L. H., Hanson, M. E., Dong, Q., Shah, A. K., & Brudi, P. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-127 · Cited by 13
“Many patients at high cardiovascular risk and/or with severely elevated LDL-C do not achieve the rigorous treatment targets recommended by European, Canadian and US guidelines using established statin treatment regimens[1,2,10,11].”
BackgroundKrysiak, R. G., Gdula‐Dymek, A., Ścieszka, J., & Okopień, B. (2010) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2010.00633.x · Cited by 11
Antisense Oligonucleotides, microRNAs, and Antibodies
Dávalos, A., & Chroni, A. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_22 · Cited by 11
“However, a significant proportion of patients treated with statins fail to achieve the recommended levels of LDL-C (Catapano 2009).”
BackgroundAntilipidemic Drug Therapy Today and in the Future
Kramer, W. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_15 · Cited by 8
Rusali, R., Shahar, S., Lee, X., & Manaf, Z. A. (2016) · Jurnal Sains Kesihatan Malaysia · doi:10.17576/jskm-2016-1402-06 · Cited by 10
“This observed outcome was probably due to the fact that women were more committed and motivated in allocation to the entire planned programme (Catapano 2009).”
ResultAshen, M. D., & Foody, J. M. (2009) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0b013e3181b4bab4 · Cited by 10
“If elevations persist, combination therapy of a lower statin dose with ezetimibe, a bile acid sequestrant, or niacin is an option.(28)”
BackgroundQuek, R. G. W., Fox, K. M., Wang, L., Lü, L., Gandra, S. R., & Wong, N. D. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000132 · Cited by 7
Determinants of Treatment Modification in Hypercholesterolemic Patients.
Wang, K.-F., Wu, C., Chang, C., Chen, L., Wang, K.-L., Lu, T., Lin, S., & Chiang, C. (2017) · PubMed Central · doi:10.6515/acs20161215a · Cited by 5
Kohli, P., & Giugliano, R. P. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413480270 · Cited by 4
Effect of Pomegranate Juice on Lipid Profile and Antioxidant Enzymes in Hypercholesterolemic
Almoraie, M., Arafat, R. A. A., & Al-RasheediI, A. A. (2013) · Cited by 10
Civeira, F., Dan, A. G., Ling, P. K. H., Hanson, M. E., Massaad, R., Milardo, C., & Triscari, J. M. (2011) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(11)70088-5 · Cited by 1
“Despite substantial lipid-lowering with the use of statins, a considerable number of patients at high cardiovascular risk and/or with severely elevated low-density lipoprotein cholesterol (LDL-C) do not achieve the rigorous treatment targets recommended by European, Canadian and US guidelines [1-4].”
BackgroundFarnier, M., Viigimaa, M., Vaverková, H., Averna, M. R., Missault, L. H., Dong, Q., Shah, A. K., Hanson, M. E., & Brudi, P. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.03.028
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Hsu, H.-Y., Lin, C.-J., Lee, Y.-S., Wu, T.-H., & Chien, K. (2020) · Figshare · doi:10.6084/m9.figshare.12650676
Metadata
- Authors
- Catapano, A. L.
- Affiliations
- University of Milan (IT)
- Corresponding author
- Catapano, Alberico L.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2008-12-23
- Volume
- 25
- Issue
- 2
- Pages
- 431-447
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2066666645
- Cited by
- 40
- References
- 97
- Citations by year
- 2020: 2 · 2017: 2 · 2016: 3 · 2015: 4 · 2014: 4 · 2013: 3 · 2012: 4
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- cholesterol, LDL-C goal attainment, statins, ezetimibe, nicotinic acid, lipid-lowering therapy, high cardiovascular risk, coronary artery disease, APOE ε4, medication adherence, combination therapy, cardiovascular risk reduction
- MeSH terms
- Anticholesteremic Agents, Drug Therapy, Combination, Europe, United Kingdom, Humans, Cholesterol, LDL, United States, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.